Replies to post #25171 on The Rising Influence of Rising Affluence

[DewDiligence]

ABT’s Freestyle Libre (continuous glucose monitor) logged 2021 sales of $3.7B, +35% YoY. That qualifies as a mega-blockbuster for a medical device.

[DewDiligence]

ABT’s COVID-diagnostics sales have been a proxy for the trajectory of the pandemic per se. These are the numbers for the trailing seven quarters:

4Q21 $2.3B
3Q21 $1.9B
2Q21 $1.5B
1Q21 $2.2B

4Q20 $2.4B
3Q20 $0.9B
2Q20 $0.6B

ABT reports 1Q22 financials tomorrow morning.